Inscription à l’infolettre

Publication — IRIC

Development of a high-throughput assay to identify inhibitors of the ubiquitin-conjugating enzyme UBCH10.

UBCH10 is an ubiquitin-conjugating enzyme (E2) of the anaphase-promoting complex E3 ligase, a key regulator of the cell cycle. The UBCH10 gene and protein are frequently upregulated in multiple solid tumors, associated with an unfavorable outcome. Accumulating evidence from studies of human cancer cell lines, mouse transgenic models, and analyses of clinical samples suggest that UBCH10 is a potential cancer drug target. No small molecule inhibitor of UBCH10 has been reported in the literature. Here, we described the development and optimization of a novel time-resolved fluorescence resonance energy transfer (TR-FRET) UBCH10 assay based on the self-polyubiquitination of the enzyme in the absence of E3. The homogenous assay is robust, sensitive, and scalable to different multi-well formats for high-throughput screening (HTS). We demonstrate the suitability of the TR-FRET assay to identify chemical inhibitors of UBCH10 in a pilot HTS campaign.

Date de publication
1st June 2022
Cléroux P, Voisin L, Meloche S
Référence PubMed
SLAS Discov 2022;27(4):266-271
ID PubMed
Institute for Research in Immunology and Cancer, Montreal, Quebec, Canada.